Equities analysts expect Cellular Biomedicine Group Inc (NASDAQ:CBMG) to post earnings of ($0.53) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Cellular Biomedicine Group’s earnings, with the highest EPS estimate coming in at ($0.50) and the lowest estimate coming in at ($0.55). Cellular Biomedicine Group also posted earnings per share of ($0.53) in the same quarter last year. The company is expected to report its next earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Cellular Biomedicine Group will report full-year earnings of ($2.09) per share for the current year, with EPS estimates ranging from ($2.28) to ($1.90). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.97) per share. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Cellular Biomedicine Group.
Cellular Biomedicine Group (NASDAQ:CBMG) last announced its quarterly earnings data on Tuesday, February 19th. The biotechnology company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.01). Cellular Biomedicine Group had a negative net margin of 17,921.62% and a negative return on equity of 42.41%. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million.
A number of equities research analysts have recently commented on the company. BidaskClub downgraded Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a research report on Friday, April 19th. Robert W. Baird initiated coverage on shares of Cellular Biomedicine Group in a research note on Wednesday, February 6th. They set an “outperform” rating and a $26.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Cellular Biomedicine Group has a consensus rating of “Buy” and a consensus price target of $27.67.
Large investors have recently made changes to their positions in the business. Vanguard Group Inc raised its stake in Cellular Biomedicine Group by 4.2% during the 3rd quarter. Vanguard Group Inc now owns 183,828 shares of the biotechnology company’s stock valued at $3,337,000 after purchasing an additional 7,443 shares during the period. Meeder Asset Management Inc. raised its stake in Cellular Biomedicine Group by 1,235.7% during the 4th quarter. Meeder Asset Management Inc. now owns 3,446 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 3,188 shares during the period. Metropolitan Life Insurance Co. NY acquired a new stake in Cellular Biomedicine Group during the 4th quarter valued at $81,000. Vanguard Group Inc. raised its stake in Cellular Biomedicine Group by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 183,828 shares of the biotechnology company’s stock valued at $3,337,000 after purchasing an additional 7,443 shares during the period. Finally, BlackRock Inc. raised its stake in Cellular Biomedicine Group by 7.7% during the 3rd quarter. BlackRock Inc. now owns 634,006 shares of the biotechnology company’s stock valued at $11,508,000 after purchasing an additional 45,154 shares during the period. 11.34% of the stock is currently owned by institutional investors.
Shares of NASDAQ:CBMG traded up $0.05 on Wednesday, reaching $16.63. 16,667 shares of the company traded hands, compared to its average volume of 47,889. Cellular Biomedicine Group has a fifty-two week low of $12.04 and a fifty-two week high of $25.00. The company has a market capitalization of $300.84 million, a PE ratio of -8.15 and a beta of 2.81.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
Read More: What is a Tariff?
Get a free copy of the Zacks research report on Cellular Biomedicine Group (CBMG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com